Cartesian Therapeutics, Inc. (RNAC) Free cash flow 2016–2025
Cartesian Therapeutics, Inc. (RNAC) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$79.4MFY2025 · since FY2016: -$20.3M → -$79.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$79.4M | -142.3% |
| FY2024 | -$32.8M | +36.2% |
| FY2023 | -$51.4M | -56.5% |
| FY2022 | -$32.8M | +46.6% |
| FY2021 | -$61.5M | -280.4% |
| FY2020 | $34.1M | +166.2% |
| FY2019 | -$51.5M | +14.3% |
| FY2018 | -$60.0M | -13.8% |
| FY2017 | -$52.8M | -159.3% |
| FY2016 | -$20.3M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice